Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical surveillance versus rivaroxaban for low-risk isolated subsegmental pulmonary embolism
NL-OMON55205Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in pulmonary embolism (PE) and venous thromboembolism (VTE), sponsored by Leiden University Medical Center. Started Sep 2021; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON55205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55205.